Wordt geladen...
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
OBJECTIVE: To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice (BID) or three times (TID) daily in patients with mild to moderate Alzheimer's disease (AD). METHODS: This was a 26 week international, randomised, double blind, placebo controlled study in which...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMJ Group
2007
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2117538/ https://ncbi.nlm.nih.gov/pubmed/17353259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp.2006.099424 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|